Main > ONCOLOGY (**) > Lung>NSCLC>EGFR+>MET>*** > Treatment > Co: UK. A. Osimertinib
Co: UK. A. Osimertinib's subsections
(*) BR 1st Line OK: 2018. 04.16.
(*) CA 2nd Line OK: 2016. 07.11.
(*) CN 2nd Line OK: 2017. 03.27.
(*) JP Approval Date: 2022. 08.25
(*) USA 1st Line OK: 2018. 04.18.
(*) USA 2nd Line OK: 2017. 03.30.
2nd Line>
Companion Diagnostics Test>
Company
EGFR mutations>
Patent>Assignee; Claims; No.; Etc.
Patent>UpDate: 2016. 08.09.
RTM
RTM Web-Site
Co: UK. A. Osimertinib's products
This section has no products